Ademi Z, Watts GF, Pang J et al (2014) Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 8:390–400. https://doi.org/10.1016/j.jacl.2014.05.008
Article
PubMed
Google Scholar
Ademi Z, Sutherland CS, Van Stiphout J et al (2017) A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. J Thromb Thrombolysis 44:494–506. https://doi.org/10.1007/s11239-017-1554-5
Article
PubMed
Google Scholar
Akhmetov I, Bubnov RV (2015) Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J 6:19. https://doi.org/10.1186/s13167-015-0041-3
Article
PubMed
PubMed Central
Google Scholar
Alagoz O, Durham D, Kasirajan K (2016) Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenom J 16:129–136. https://doi.org/10.1038/tpj.2015.39
CAS
Article
Google Scholar
Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19–32. https://doi.org/10.1080/1364557032000119616
Article
Google Scholar
Balentine CJ, Vanness DJ, Schneider DF (2017) Cost-effectiveness of lobectomy versus genetic testing (Afirma(R)) for indeterminate thyroid nodules: considering the costs of surveillance. Surgery. https://doi.org/10.1016/j.surg.2017.10.004
Article
PubMed
PubMed Central
Google Scholar
Barzi A, Sadeghi S, Kattan MW, Meropol NJ (2015) Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv005
Article
PubMed
PubMed Central
Google Scholar
Beaulieu M, de Denus S, Lachaine J (2010) Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 11:1573–1590. https://doi.org/10.2217/pgs.10.145
CAS
Article
PubMed
Google Scholar
Berm EJ, Looff M, Wilffert B et al (2016) Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One 11:e0146262. https://doi.org/10.1371/journal.pone.0146262
CAS
Article
PubMed
PubMed Central
Google Scholar
Brown GC, Brown MM, Lieske HB et al (2015) A value-based medicine cost-utility analysis of genetic testing for neovascular macular degeneration. Int J Retina Vitr 1:19. https://doi.org/10.1186/s40942-015-0016-5
Article
Google Scholar
Brüggenjürgen B, Kornbluth L, Ferrara JV et al (2012) Herausforderungen an die klinische Evaluation und Gesundheitsökonomie auf dem Weg zur personalisierten Medizin. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 55:710–714. https://doi.org/10.1007/s00103-012-1479-2
Article
PubMed
Google Scholar
Buchanan J, Wordsworth S, Clifford R et al (2017) Using genomic information to guide ibrutinib treatment decisions in chronic lymphocytic leukaemia: a cost-effectiveness analysis. PharmacoEconomics. https://doi.org/10.1007/s40273-017-0519-z
Article
PubMed
PubMed Central
Google Scholar
Cesuroglu T, Syurina E, Feron F et al (2016) Other side of the coin for personalised medicine and healthcare: content analysis of ‘personalised’ practices in the literature BMJ open 6:e010243. https://doi.org/10.1136/bmjopen-2015-010243
Article
PubMed
Google Scholar
Chen Y-E, Kao S-S, Chung R-H, Toland AE (2016) Cost-effectiveness analysis of different genetic testing strategies for Lynch syndrome in taiwan. PLoS One 11(8):e0160599
Article
Google Scholar
Chong HY, Saokaew S, Dumrongprat K et al (2014) Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thromb Res 134:1278–1284. https://doi.org/10.1016/j.thromres.2014.10.006
CAS
Article
PubMed
Google Scholar
Coate LE, Leighl NB (2011) How affordable are targeted therapies in non-small cell lung cancer? Curr Treat Options Oncol 12:1–11. https://doi.org/10.1007/s11864-010-0137-x
Article
PubMed
Google Scholar
Conti R, Veenstra DL, Armstrong K et al (2010) Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Mak Int J Soc Med Decis Mak 30:328–340. https://doi.org/10.1177/0272989X09347014
Article
Google Scholar
D’Andrea E, Marzuillo C, Pelone F et al (2015) Genetic testing and economic evaluations: a systematic review of the literature. Epidemiol Prev 39:45–50
PubMed
Google Scholar
D’Andrea E, Marzuillo C, De Vito C et al (2016) Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med 18:1171–1180. https://doi.org/10.1038/gim.2016.29
Article
PubMed
PubMed Central
Google Scholar
Dong D, Tan-Koi W-C, Teng GG, Finkelstein E, Sung C (2015) Cost–effectiveness analysis of genotyping for and an enhanced safety program in gout patients starting allopurinol in Singapore. Pharmacogn 16(16):1781–1793
CAS
Google Scholar
Drummond MF, Sculpher MJ, Claxton K et al (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
Google Scholar
European Commission (2013) Commission staff working document. Use of “-omics” technologies in the development of personalised medicine. European Commission, Brussels
Google Scholar
Faulkner E, Annemans L, Garrison L et al (2012) Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health J Int Soc Pharmacoecon Outcomes Res 15:1162–1171. https://doi.org/10.1016/j.jval.2012.05.006
Article
Google Scholar
Ferrusi IL, Marshall DA, Kulin NA et al (2009) Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Pers Med 6:193–215. https://doi.org/10.2217/17410541.6.2.193
CAS
Article
Google Scholar
Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL (2015) Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. J Clin Oncol 33(18):2084–2091
CAS
Article
Google Scholar
Garrison LP Jr, Kamal-Bahl S, Towse A (2017) Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health J Int Soc Pharmacoecon Outcomes Res 20:213–216. https://doi.org/10.1016/j.jval.2016.12.005
Article
Google Scholar
Goldie SJ, Levin AR (2001) Genomics in medicine and public health: role of cost-effectiveness analysis. JAMA 286:1637–1638. https://doi.org/10.1001/jama.286.13.1637-JMS1003-5-1
CAS
Article
PubMed
Google Scholar
Gonzalez FM, Veneziano MA, Puggina A et al (2015) A systematic review on the cost-effectiveness of genetic and electrocardiogram testing for long QT syndrome in infants and young adults. Value Health J Int Soc Pharmacoecon Outcomes Res 18:700–708. https://doi.org/10.1016/j.jval.2015.03.1788
Article
Google Scholar
Goverde A, Spaander MCW, van Doorn HC, Dubbink HJ, van den Ouweland AMW, Tops CM, Kooi SG, de Waard J, Hoedemaeker RF, Bruno MJ, Hofstra RMW, de Bekker-Grob EW, Dinjens WNM, Steyerberg EW, Wagner A (2016) Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70 years of age. Gynecol Oncol 143(3):453–459
Article
Google Scholar
Green LE, Dinh TA, Hinds DA et al (2014) Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy. Appl Health Econ Health Policy 12:203–217. https://doi.org/10.1007/s40258-014-0089-6
Article
PubMed
Google Scholar
Grosse SD (2015) When is genomic testing cost-effective? Testing for lynch syndrome in patients with newly-diagnosed colorectal cancer and their relatives. Healthcare 3:860–878. https://doi.org/10.3390/healthcare3040860
Article
PubMed
PubMed Central
Google Scholar
Grosse SD, Wordsworth S, Payne K (2008) Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 10:648–654. https://doi.org/10.1097/GIM.0b013e3181837217
Article
PubMed
Google Scholar
Hatz MH, Schremser K, Rogowski WH (2014) Is individualized medicine more cost-effective? A systematic review. PharmacoEconomics 32:443–455. https://doi.org/10.1007/s40273-014-0143-0
Article
PubMed
Google Scholar
Horster L, Schlenk RF, Stadler M et al (2017) Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. Leuk Res 62:84–90. https://doi.org/10.1016/j.leukres.2017.09.009
Article
PubMed
Google Scholar
Husereau D, Marshall DA, Levy AR et al (2014) Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making? Int J Technol Assess Health Care 30:179–187. https://doi.org/10.1017/S0266462314000142
Article
PubMed
Google Scholar
Institute of Medicine (2013) The economics of genomic medicine: workshop summary. National Academies Press, Washington, DC. https://doi.org/10.17226/18276
Book
Google Scholar
Jahn B, Rochau U, Kurzthaler C et al (2015) Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. SpringerPlus 4:752. https://doi.org/10.1186/s40064-015-1440-6
CAS
Article
PubMed
PubMed Central
Google Scholar
Jahn B, Rochau U, Kurzthaler C et al (2017) Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC Cancer 17:685. https://doi.org/10.1186/s12885-017-3603-z
Article
PubMed
PubMed Central
Google Scholar
Ke CH, Chung WH, Wen YH et al (2017) Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol 44:835–843. https://doi.org/10.3899/jrheum.151476
CAS
Article
PubMed
Google Scholar
Lazaro P, Perez de Isla L, Watts GF et al (2017) Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol 11:260–271. https://doi.org/10.1016/j.jacl.2017.01.002
Article
PubMed
Google Scholar
Lee WS, Palmer BJ, Garcia A et al (2014) BRAF mutation in papillary thyroid cancer: a cost-utility analysis of preoperative testing. Surgery 156:1569–1577. https://doi.org/10.1016/j.surg.2014.08.051(discussion 1577–1568)
Article
PubMed
Google Scholar
Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ (2017) A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health 20(4):547–555
Article
Google Scholar
Lieberthal RD (2013) Economics of genomic testing for women with breast cancer. Am J Managed Care 19:1024–1031
Google Scholar
Lim EA, Lee H, Bae E et al (2016) Economic evaluation of companion diagnostic testing for EGFR mutations and first-line targeted therapy in advanced non-small cell lung cancer patients in South Korea. PLoS ONE 11:e0160155. https://doi.org/10.1371/journal.pone.0160155
CAS
Article
PubMed
PubMed Central
Google Scholar
Lu S, Zhang J, Ye M, Wang B, Wu B (2016) Economic analysis of testing and crizotinib therapy for advanced non-small-cell lung cancer. Pharmacogn 17(9):985–994
CAS
Google Scholar
Manchanda R, Legood R, Burnell M et al (2015) Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst 107:380. https://doi.org/10.1093/jnci/dju380
CAS
Article
PubMed
Google Scholar
Martes-Martinez C, Mendez-Sepulveda C, Millan-Molina J et al (2017) Cost-utility study of warfarin genotyping in the VACHS affiliated anticoagulation clinic of Puerto Rico. Puerto Rico Health Sci J 36:165–172
Google Scholar
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
Article
PubMed
PubMed Central
Google Scholar
Moretti ME, Lato DF, Berger H et al (2017) A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. Pharmacogenom J. https://doi.org/10.1038/tpj.2017.33
Article
Google Scholar
National Institute of Health NIH (2016) The cost of sequencing a human genome. https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/. Accessed 4 Dec 2017
Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H (2015) Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer 90(1):71–77
Article
Google Scholar
Naylor RN, John PM, Winn AN et al (2014) Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care 37:202–209. https://doi.org/10.2337/dc13-0410
Article
PubMed
Google Scholar
NCBI. GTR: Genetic Testing Registry (2017) GTR data. NCBI. https://www.ncbi.nlm.nih.gov/gtr/. Accessed 3 Dec 2017
Nguyen HV, Finkelstein EA, Mital S et al (2017) Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. J Med Genet 54:747–753. https://doi.org/10.1136/jmedgenet-2017-104670
CAS
Article
PubMed
Google Scholar
Nimmesgern E, Benediktsson I, Norstedt I (2017) Personalized medicine in Europe. Clin Transl Sci 10:61–63. https://doi.org/10.1111/cts.12446
CAS
Article
PubMed
PubMed Central
Google Scholar
Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L (2014) Touchette DR Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada) 12(3):438
Article
Google Scholar
Patrinos GP, Mitropoulou C (2017) Measuring the value of pharmacogenomics evidence. Clin Pharmacol Ther 102:739–741. https://doi.org/10.1002/cpt.743
CAS
Article
PubMed
Google Scholar
Phillips KA, Ann Sakowski J, Trosman J et al (2014) The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 16:251–257. https://doi.org/10.1038/gim.2013.122
Article
PubMed
Google Scholar
Pink J, Pirmohamed M, Lane S et al (2014) Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther 95:199–207. https://doi.org/10.1038/clpt.2013.190
CAS
Article
PubMed
Google Scholar
Plothner M, Ribbentrop D, Hartman JP et al (2016) Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany. Adv Ther 33:1461–1480. https://doi.org/10.1007/s12325-016-0376-8
Article
PubMed
PubMed Central
Google Scholar
Plumpton CO, Yip VL, Alfirevic A et al (2015) Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia 56:556–563
Article
Google Scholar
Plumpton CO, Roberts D, Pirmohamed M et al (2016) A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. PharmacoEconomics 34:771–793. https://doi.org/10.1007/s40273-016-0397-9
Article
PubMed
Google Scholar
Ross S, Anand SS, Joseph P et al (2012) Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis 1:15. https://doi.org/10.1258/cvd.2012.012001
Article
Google Scholar
Rosso A, Pitini E, D’Andrea E et al (2017) The cost-effectiveness of genetic screening for familial hypercholesterolemia: a systematic review. Ann Ig Med Prev Comunita 29:464–480. https://doi.org/10.7416/ai.2017.2178
CAS
Article
Google Scholar
Rubio-Terres C, Soria JM, Morange PE et al (2015) Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism. Appl Health Econ Health Policy 13:233–242. https://doi.org/10.1007/s40258-015-0153-x
CAS
Article
PubMed
PubMed Central
Google Scholar
Ruiz-Iruela C, Padulles-Zamora N, Podzamczer-Palter D et al (2016) HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience. Pharmacogenet Genom 26:390–396. https://doi.org/10.1097/fpc.0000000000000229
CAS
Article
Google Scholar
Saokaew S, Tassaneeyakul W, Maenthaisong R et al (2014) Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS One 9:e94294. https://doi.org/10.1371/journal.pone.0094294
CAS
Article
PubMed
PubMed Central
Google Scholar
Schackman BR, Haas DW, Park SS, Cynthia Li X, Freedberg KA (2015) Cost–effectiveness of genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics 16(18):2007–2018
CAS
Article
Google Scholar
Schremser K, Rogowski WH, Adler-Reichel S et al (2015) Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on egfr mutation testing in advanced lung adenocarcinoma patients in Germany. PharmacoEconomics 33:1215–1228. https://doi.org/10.1007/s40273-015-0305-8
Article
PubMed
Google Scholar
Shabaruddin FH, Fleeman ND, Payne K (2015) Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenom Pers Med 8:115–126. https://doi.org/10.2147/PGPM.S35063
Article
Google Scholar
Shiffman D, Perez MV, Bare LA et al (2015) Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. BMC Cardiovasc disord 15:104. https://doi.org/10.1186/s12872-015-0100-7
CAS
Article
PubMed
PubMed Central
Google Scholar
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2014) A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 18(58):1–406
Article
Google Scholar
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2015) A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer 15:313
Article
Google Scholar
Snowsill T, Coelho H, Huxley N et al (2017) Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess 21:1–238. https://doi.org/10.3310/hta21510
Article
PubMed
PubMed Central
Google Scholar
Terkola R, Antonanzas F, Postma M (2017) Economic evaluation of personalized medicine: a call for real-world data. Eur J Health Econ. https://doi.org/10.1007/s10198-017-0890-x
Article
PubMed
Google Scholar
U.S. National Library of Medicine (2017) Medical subjects heading (MeSH). Precision medicine MeSH descriptor data 2017. National Institute of Health (NIH). https://meshb.nlm.nih.gov/record/ui?ui=D057285. Accessed 19 Sept 2017
Veenstra DL, Higashi MK, Phillips KA (2000) Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2:80–90. https://doi.org/10.1208/ps020329
Article
PubMed Central
Google Scholar
Vegter S, Jansen E, Postma MJ et al (2010) Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Dev Res 71:492–501. https://doi.org/10.1002/ddr.20424
CAS
Article
Google Scholar
Verbelen M, Weale ME, Lewis CM (2017) Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenom J 17:395–402. https://doi.org/10.1038/tpj.2017.21
CAS
Article
Google Scholar
Verhoef TI, Redekop WK, Langenskiold S et al (2016) Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenom J 16:478–484. https://doi.org/10.1038/tpj.2016.41
CAS
Article
Google Scholar
Waldman SA, Terzic A (2008) Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther 84:179–182. https://doi.org/10.1038/clpt.2008.142
CAS
Article
PubMed
Google Scholar
Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE (2016) A personalized paradigm in the treatment of platinum-resistant ovarian cancer – a cost utility analysis of genomic-based versus cytotoxic therapy. Gynecol Oncol 142(1):144–149
CAS
Article
Google Scholar
Wang Y, Yan BP, Liew D et al (2017) Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenom J. https://doi.org/10.1038/tpj.2016.94
Article
Google Scholar
Wong WB, Carlson JJ, Thariani R et al (2010) Cost effectiveness of pharmacogenomics: a critical and systematic review. PharmacoEconomics 28:1001–1013. https://doi.org/10.2165/11537410-000000000-00000
Article
PubMed
Google Scholar
Yamauchi H, Nakagawa C, Yamashige S, Takei H, Yagata H, Yoshida A, Hayashi N, Hornberger J, Yu T, Chao C, Yoshizawa C, Nakamura S (2014) Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stagebreast cancer in Japan. BMC Health Services Research 14(1)
You JH (2014) Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. Pharmacogn Genom 24:6–14
CAS
Article
Google Scholar
You JH (2015) Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics 16(10):1089–1100
CAS
Article
Google Scholar